Lonza and RION have entered a collaboration to scale commercial manufacturing of RION’s Purified Exosome Product (PEP), a platform candidate with immunomodulatory and regenerative properties. Lonza will produce PEP drug substance at its Houston facility, leveraging its expertise in extracellular vesicles to support late-phase clinical and commercial supplies. RION’s proprietary biomanufacturing platform facilitates production of stable, lyophilized exosomes with applications across multiple therapeutic areas. This partnership enables accelerated patient access to innovative biologic treatments in regenerative medicine and immunology.